Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk Mortality (b) 22% ICU admission 22% Hospitalization 3% Mortality (c) 8% Mortality (d) 16% ICU admission (b) 39% Hospitalization (b) -2% c19early.org/mf Ojeda-Fernández et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? PSM retrospective 13,112 patients in Italy Lower mortality (p<0.0001) and ICU admission (p=0.013) Ojeda-Fernández et al., Diabetes, Obesity and Me.., doi:10.1111/dom.14648 Favors metformin Favors control
Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy
Ojeda-Fernández et al., Diabetes, Obesity and Metabolism, doi:10.1111/dom.14648
Ojeda-Fernández et al., Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic.., Diabetes, Obesity and Metabolism, doi:10.1111/dom.14648
Jan 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 31,966 COVID+ patients using anti-hyperglycemic drugs in Italy, showing lower mortality and ICU admission with metformin use.
risk of death, 16.2% lower, RR 0.84, p < 0.001, treatment 1,476 of 6,556 (22.5%), control 1,787 of 6,556 (27.3%), NNT 21, odds ratio converted to relative risk, propensity score matching.
risk of death, 22.1% lower, RR 0.78, p < 0.001, treatment 968 of 6,556 (14.8%), control 1,261 of 6,556 (19.2%), NNT 22, odds ratio converted to relative risk, in-hospital mortality, propensity score matching.
risk of ICU admission, 22.4% lower, RR 0.78, p = 0.01, treatment 166 of 6,556 (2.5%), control 212 of 6,556 (3.2%), NNT 143, odds ratio converted to relative risk, propensity score matching.
risk of hospitalization, 2.7% lower, RR 0.97, p = 0.11, treatment 3,551 of 6,556 (54.2%), control 3,670 of 6,556 (56.0%), NNT 55, odds ratio converted to relative risk, propensity score matching.
risk of death, 8.3% lower, RR 0.92, p = 0.06, treatment 793 of 3,297 (24.1%), control 876 of 3,297 (26.6%), NNT 40, odds ratio converted to relative risk, excluding patients previously treated with insulin, propensity score matching.
risk of death, 16.0% lower, RR 0.84, p = 0.003, treatment 512 of 3,297 (15.5%), control 618 of 3,297 (18.7%), NNT 31, odds ratio converted to relative risk, excluding patients previously treated with insulin, in-hospital mortality, propensity score matching.
risk of ICU admission, 39.2% lower, RR 0.61, p = 0.002, treatment 64 of 3,297 (1.9%), control 102 of 3,297 (3.1%), NNT 87, odds ratio converted to relative risk, excluding patients previously treated with insulin, propensity score matching.
risk of hospitalization, 2.2% higher, RR 1.02, p = 0.36, treatment 1,822 of 3,297 (55.3%), control 1,792 of 3,297 (54.4%), odds ratio converted to relative risk, excluding patients previously treated with insulin, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ojeda-Fernández et al., 10 Jan 2022, retrospective, Italy, peer-reviewed, 11 authors.
Contact: luisa.ojeda@marionegri.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy. Luisa Ojeda-Fernández PhD1, Andreana Foresta MSc1, Giulia Macaluso MSc1, Pierluca Colacioppo MSc1, Mauro Tettamanti MSc2, Antonella Zambon MSc3, Stefano Genovese MD4, Ida Fortino MSc5, Olivia Leoni MSc5, Maria Carla Roncaglioni MSc 1, Marta Baviera Pharm Dr1 1 Laboratory of Cardiovascular Prevention, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. 2 Laboratory of Geriatric Neuropsychiatry, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy. 3 Department of Statistics and Quantitative Methods, University of Milano Bicocca, Milano, Italy 4 Centro Cardiologico Monzino IRCCS, Milan, Italy 5 Unità Organizzativa Osservatorio Epidemiologico Regionale, Lombardy Region, Milan, Italy. Correspondence Dr. Luisa Ojeda Fernández Laboratory of Cardiovascular Prevention Department of Cardiovascular Medicine Istituto di Ricerche Farmacologiche Mario Negri IRCCS Via Mario Negri 2, 20156 Milan, Italy Tel: +39 0239014561 e-mail: luisa.ojeda@marionegri.it This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.14648 This article is protected by copyright. All rights reserved. ABSTRACT Aims. We compared the association of metformin use and COVID-19 outcomes in a cohort of 31,966 patients with diabetes in Lombardy. Methods. We used a COVID-19 linkable administrative regional database to select diabetic patients over 40 years old. They had at least two prescriptions of antidiabetic drugs in 2019 and a positive test for SARS-CoV-2 between 15 February 2020 and 15 March 2021. The association of metformin use and clinical outcomes was assessed by multivariable logistic regression analyses and after propensity score matching. Clinical outcomes were all-cause mortality, in-hospital mortality, hospitalization for COVID-19 and admission to an intensive care unit (ICU). Results. In multivariable models metformin use was associated with a significantly lower risk of total mortality (OR 0.70; 95% CI 0.66-0.75), in-hospital mortality (OR 0.68; 95% CI 0.63-0.73), hospitalization for COVID-19 (OR 0.86; 95% CI 0.81-0.91) and ICU admission (OR 0.81; 95% CI 0.69-0.94) compared with metformin non-users. Results were similar in propensity score analysis; metformin was associated with significantly lower risk of total mortality (OR 0.79; 95% CI, 0.730.86), in-hospital mortality (OR 0.74; 95% CI, 0.67-0.81) and ICU admission (OR 0.77; 95% CI, 0.63-0.95). Conclusions. In this large cohort, metformin use was associated with a protective effect in COVID19 clinical outcomes, suggesting that it might be a potentially useful drug to prevent severe COVID19 disease, although randomized clinical trials (RCT) are needed to confirm this. While awaiting the results of RCT, we suggest continuing prescribing metformin to diabetic patients with COVID-19. Keywords COVID-19, Diabetes Mellitus, Metformin, Outcomes This article is protected by copyright. All rights reserved.
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit